Horizontal Transfer of Tamoxifen Resistance in MCF-7 Cell Derivates: Proteome Study

References

• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233–47. doi:10.1146/annurev-med-070909-182917. PMID:20887199
   PubMed Web of Science ®Google Scholar
• Jankowitz RC, Davidson NE. Adjuvant endocrine therapy for breast cancer: How long is long enough? Oncology 2013;27:1210–6, 1224. PMID:24624537
   PubMed Web of Science ®Google Scholar
• Roop RP, Ma CX. Endocrine resistance in breast cancer: Molecular pathways and rational development of targeted therapies. Future Oncol 2012;8:273–92. doi:10.2217/fon.12.8. PMID:22409464
   PubMed Web of Science ®Google Scholar
• Fox EM, Arteaga CL, Miller TW. Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer. Front Oncol 2012;2:145. doi:10.3389/fonc.2012.00145. PMID:23087906
   PubMedGoogle Scholar
• Viedma-Rodriguez R, Baiza-Gutman L, Salamanca-Gomez F, Diaz-Zaragoza M, Martinez-Hernandez G, Ruiz Esparza-Garrido R, Velazquez-Flores MA and Arenas-Aranda D: Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep 2014;32:3–15. PMID:24841429
   PubMed Web of Science ®Google Scholar
• Scherbakov AM, Krasil'nikov MA, Kushlinskii NE. Molecular mechanisms of hormone resistance of breast cancer. Bull Exp Biol Med 2013;155:384–95. doi:10.1007/s10517-013-2160-y. PMID:24137610
   PubMed Web of Science ®Google Scholar
• Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 2005;71:201–37. doi:10.1016/S0083-6729(05)71007-4. PMID:16112269
   PubMed Web of Science ®Google Scholar
• Krasil'nikov MA. [Modern approaches to estrogen-independent growth of breast tumor]. Vopr Onkol 2004;50:399–405. PMID:15605761
   PubMedGoogle Scholar
• Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, et al. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology 2009;77(1):23–37. doi:10.1159/000258493. PMID:20130429
   PubMed Web of Science ®Google Scholar
• Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005;12(1):S37–46. doi:10.1677/erc.1.00977. PMID:16113098
   PubMed Web of Science ®Google Scholar
• Ghosh A, Awasthi S, Peterson JR, Hamburger AW. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer. Br JCancer 2013;108:557–63. doi:10.1038/bjc.2013.11. PMID:23361053
   PubMed Web of Science ®Google Scholar
• Scherbakov AM, Andreeva OE, Shatskaya VA and Krasil'nikov MA: The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem 2012;113:2147–55. doi:10.1002/jcb.24087. PMID:22307688
   PubMed Web of Science ®Google Scholar
• Moore R, Faller DV. SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol 2013;216(3):273–85. doi:10.1530/JOE-12-0102. PMID:22159506
   PubMed Web of Science ®Google Scholar
• Adams BD, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol 2009;23:1215–30. doi:10.1210/me.2009-0062
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283:31079–86. doi:10.1074/jbc.M806041200. PMID:18790736
   PubMed Web of Science ®Google Scholar
• Boettcher M, Kischkel F, Hoheisel JD. High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PloS one 2010;5:e11002. doi:10.1371/journal.pone.0011002. PMID:20544021
   PubMed Web of Science ®Google Scholar
• Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 2007;6:1089–98. doi:10.1158/1535-7163.MCT-06-0663. PMID:17363502
   PubMed Web of Science ®Google Scholar
• Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316–39. doi:10.1038/sj.onc.1206937. PMID:14576841
   PubMed Web of Science ®Google Scholar
• Panneerselvam M, Muthu K, Ramadas K. Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer. Mol BioSystems 2015;11:2998–3010. doi:10.1039/C5MB00272A. PMID:26299756
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8:175–82. doi:10.1677/erc.0.0080175. PMID:11566608
   PubMed Web of Science ®Google Scholar
• Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105–17. doi:10.1210/en.2003-0705. PMID:12960029
   PubMed Web of Science ®Google Scholar
• Colovic M, Todorovic M, Colovic N, Terzic T, Karadzic K, Jurisic V. Appearance of estrogen positive bilateral breast carcinoma with HER2 gene amplification in a patient with aplastic anemia. Pol J Pathol: Off J Po Soc Pathol 2014;65:66–9. doi:10.5114/pjp.2014.42672. PMID:25119012
   PubMed Web of Science ®Google Scholar
• Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res: BCR. 2014;16:R12. doi:10.1186/bcr3604. PMID:24457069
   PubMed Web of Science ®Google Scholar
• Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: The PMC42 model as a case study. Cells Tissues Organs 2011;193:23–40. doi:10.1159/000320174. PMID:21051859
   PubMed Web of Science ®Google Scholar
• Radenkovic S, Konjevic G, Jurisic V, Karadzic K, Nikitovic M, Gopcevic K. Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients. Cell Biochem Biophys 2014;68:143–52. doi:10.1007/s12013-013-9701-x. PMID:23812723
   PubMed Web of Science ®Google Scholar
• Berstein LM, Zheng H, Yue W, Wang JP, Lykkesfeldt AE, Naftolin F, et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer. 2003;10:267–77. doi:10.1677/erc.0.0100267. PMID:12790788
   PubMed Web of Science ®Google Scholar
• Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, et al. Adaptive hypersensitivity to estrogen: Mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 2003;10:111–30. doi:10.1677/erc.0.0100111. PMID:12790774
   PubMed Web of Science ®Google Scholar
• Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PloS one 2014;9:e95240. doi:10.1371/journal.pone.0095240. PMID:24740415
   PubMed Web of Science ®Google Scholar
• Jaiswal R, Luk F, Dalla PV, Grau GE, Bebawy M. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PloS one 2013;8:e61515. doi:10.1371/journal.pone.0061515. PMID:23593486
   PubMed Web of Science ®Google Scholar
• Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11:695–707. doi:10.1016/S1097-2765(03)00090-X. PMID:12667452
   PubMed Web of Science ®Google Scholar
• Mruk DD, Cheng CY. Enhanced chemiluminescence (ECL) for routine immunoblotting: An inexpensive alternative to commercially available kits. Spermatogenesis 2011;1:121–122. doi:10.4161/spmg.1.2.16606. PMID:22319660
   PubMedGoogle Scholar
• Bryukhovetskiy A, Shevchenko V, Kovalev S, Chekhonin V, Baklaushev V, Bryukhovetskiy I, et al. To the novel paradigm of proteome-based cell therapy of tumors: Through comparative proteome mapping of tumor stem cells and tissue-specific stem cells of humans. Cell Transplant 2014;23(1):S151–70. doi:10.3727/096368914X684907. PMID:25303679
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer. 2010;102:639–44. doi:10.1038/sj.bjc.6605530. PMID:20087353
   PubMed Web of Science ®Google Scholar
• Naipal KA, Raams A, Bruens ST, Brandsma I, Verkaik NS, Jaspers NG, et al. Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer. PloS one 2015;10:e0126029. doi:10.1371/journal.pone.0126029. PMID:25927440
   PubMed Web of Science ®Google Scholar
• Naderi A, Vanneste M. Prolactin-induced protein is required for cell cycle progression in breast cancer. Neoplasia 2014;16(329–42):e1–14.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang J, Qian J, Liu Z, Chen H, Cui Z. S100A14, a mediator of epithelial-mesenchymal transition, regulates proliferation, migration and invasion of human cervical cancer cells. Am J Cancer Res 2015;5:1484–95. PMID:26101712
   PubMed Web of Science ®Google Scholar
• Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: A new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res: BCR 2015;17:69. PMID:25990368
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao X, Xiao Q, Liu Q, Ding K, Yu F, et al. Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition. J Mol Cell Biol 2014;6:352–4. PMID:24916398
   PubMed Web of Science ®Google Scholar
• De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, et al. 4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology. 2016;10:24–39. PMID:26285647
   PubMed Web of Science ®Google Scholar
• De Marchi T, Kuhn E, Dekker LJ, Stingl C, Braakman RB, Opdam M, et al. Targeted MS assay predicting tamoxifen resistance in estrogen-receptor-positive breast cancer tissues and sera. J Proteome Res 2016;15:1230–42. PMID:26958999
   PubMed Web of Science ®Google Scholar
• Bronnum H, Andersen DC, Schneider M, Sandberg MB, Eskildsen T, et al. miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1. PLoS One 2013;8:e56280. PMID:23441172
   PubMed Web of Science ®Google Scholar
• Pavlikova N, Bartonova I, Balusikova K, Kopperova D, Halada P, Kovar J. Differentially expressed proteins in human MCF-7 breast cancer cells sensitive and resistant to paclitaxel. Exp Cell Res 2015;333:1–10. PMID:25557873
   PubMed Web of Science ®Google Scholar
• Pasquier J, Magal P, Boulange-Lecomte C, Webb G, Le Foll F. Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: A cell population dynamics model. Biol Direct 2011;6:5. PMID:21269489
   PubMed Web of Science ®Google Scholar
• Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Research and Treatment. 2014;147:423–31. PMID:25007959
   PubMed Web of Science ®Google Scholar
• Scherbakov AM, Stefanova LB, Sorokin DV, Semina SE, Berstein LM, Krasil'nikov MA. Snail/beta-catenin signaling protects breast cancer cells from hypoxia attack. Exp Cell Res 2013;319:3150–9. PMID:23973669
   PubMed Web of Science ®Google Scholar
• Yamaga R, Ikeda K, Boele J, Horie-Inoue K, Takayama K, Urano T, et al. Systemic identification of estrogen-regulated genes in breast cancer cells through cap analysis of gene expression mapping. Biochem Biophys Res Commun 2014;447:531–6. doi:10.1016/j.bbrc.2014.04.033. PMID:24746470
   PubMed Web of Science ®Google Scholar
• Yi W, Peng J, Zhang Y, Fu F, Zou Q, Tang Y. Differential protein expressions in breast cancer between drug sensitive tissues and drug resistant tissues. Gland Surg 2013;2:62–8. PMID:25083461
   PubMedGoogle Scholar
• Moon JS, Kim HE, Koh E, Park SH, Jin WJ, Park BW, et al. Kruppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem 2011;286:23808–16. doi:10.1074/jbc.M111.236737. PMID:21586797
   PubMed Web of Science ®Google Scholar
• Vanneste M, Naderi A. Prolactin-Induced Protein regulates cell adhesion in breast cancer. Biochem Biophys Res Commun 2015;468:850–6. doi:10.1016/j.bbrc.2015.11.043. PMID:26585492
   PubMed Web of Science ®Google Scholar
• Baniwal SK, Chimge NO, Jordan VC, Tripathy D, Frenkel B. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PloS one 2014;8:e62361. doi:10.1371/journal.pone.0062361. PMID:23755096
   PubMed Web of Science ®Google Scholar
• Ali A, Creevey L, Hao Y, McCartan D, O'Gaora P, Hill A, et al. Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer. Breast Cancer Res: BCR. 2015;17:123. doi:10.1186/s13058-015-0636-6. PMID:26341737
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ichikawa-Tomikawa N, Shishito N, Nishiura K, Miura T, Hozumi A, et al. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion. BMC Cancer 2015;15:53. doi:10.1186/s12885-015-1059-6. PMID:25884418
   PubMed Web of Science ®Google Scholar